摘要
目的:初步了解吉非替尼(Iressa)单药治疗化疗失败的晚期非小细胞肺癌的近期疗效及不良反应。方法:选择住院31例非小细胞肺癌Ⅲb或Ⅳ期,并且行2个疗程以(?)含铂类药物的联合化疗后病情进展(PD)者,单剂口服Iressa 250mg,qd至出现PD。同时每周行1次胸部平片检查,每月1次胸部CT扫描。结果:31例中1例达到完全缓解(CR),7例部分缓解(PR),17例病情稳定(SD),完全缓解率为3.2%(95%可信限区间CI:0～17%),部分缓解率22.6%(95%CI:10%～41%),疾病控制率(包括所有缓解病例和病情稳定的病例)80.6%(95%CI:52%～92%)。症状缓解率为51.6%(95%CI:33%～70%),缓解最为明显的症状为咳嗽和疼痛,出现症状缓解的中位时间为14d。最常见的不良反应为1～2度的皮疹和腹泻,无1例因不良反应而退出。结论:单药口服Iressa对于经化疗治疗失败的晚期非小细胞肺癌,具有较好的疗效和耐受性。
Objective:To evaluate the efficacy anc safety of gefitinib (Iressa) on patients with advanced non-small cell lung cancer and resistant to prior chemotherapy. Methods:31 inhospitalized patients with unresectable stage Ⅲ b or Ⅳ NSCLC (non-small cell lung cancer), whose diseases were worsen or relapsed after at least 2 cycles of chemotherapy with platinum-based regimen,were recruit-ed. The patients were given with 250mg of Iressa once daily till disease progression was noted. A chest X-ray was performed weekly and a chest CT scan were taken monthly for a response assessment. Re-sults:Among the 31 patients,one had complete response(CR),7 had partial response (PR),and 17 were in stable condition. The CR rate was 3. 2 % (95% CI: 0-17% ) ; PR rate 22. 6 % (95 % CI: 10%-41% );disease control rates including both tumor responses and stable condition 80. 6% (95% CI: 52 %-92 % ); the symptom response rate 51.6% (95 % CI: 33%-70%). The symptoms of coughing and pain were significantly improved. The average period for a patient to have improved symptoms was 14 days. The most common adverse events were skin rash and diarrhea (grade 1 or 2). None of patients were withdrawn due to the adverse events. Conclusion: Monotherapy with Iressa is ef-fective and tolerable to patients with advanced NSCLC and resistant to prior chemotherapy.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2004年第6期553-555,共3页
Chinese Journal of New Drugs
关键词
非小细胞肺癌
吉非替尼
靶向治疗
化疗耐药
non-small cell lung cancer(NSCLC)
gefitinib(Iressa)
target therapy
chemotherapy resistance
